title: Limited HIV-1 Reactivation in Resting CD4+T cells from Aviremic Patients under Protease Inhibitors.
abstract: A latent viral reservoir that resides in resting CD4+T cells represents a major barrier for eradication of HIV infection. We test here the impact of HIV protease inhibitor (PI) based combination anti-retroviral therapy (cART) over nonnucleoside reverse transcriptase inhibitor (NNRTI)-based cART on HIV-1 reactivation and integration in resting CD4+T cells. This is a prospective cohort study of patients with chronic HIV-1 infection treated with conventional cART with an undetectable viremia. We performed a seven-year study of 47 patients with chronic HIV-infection treated with cART regimens and with undetectable plasma HIV-1 RNA levels for at least 1 year. Of these 47 patients treated with cART, 24 were treated with a PI-based regimen and 23 with a NNRTI-based regimen as their most recent treatment for more than one year. We evaluated the HIV-1 reservoir using reactivation assay and integrated HIV-1 DNA, respectively, in resting CD4+T cells. Resting CD4+T cells isolated from PI-treated patients compared to NNRTI-treated patients showed a limited HIV-1 reactivation upon T-cell stimulation (p = 0·024) and a lower level of HIV-1 integration (p = 0·024). Our study indicates that PI-based cART could be more efficient than NNRTI-based cART for limiting HIV-1 reactivation in aviremic chronically infected patients.
authors.affiliation: Department of Virology, Pathogens &Inflammation Laboratory, University of Franche-Comté, COMUE Bourgogne Franche-Comté University, UPRES EA4266, SFR FED 4234, CHRU Besançon, France.
authors.forename: Amit
authors.initials: A
authors.lastname: Kumar
authors.affiliation: Department of Virology, Pathogens &Inflammation Laboratory, University of Franche-Comté, COMUE Bourgogne Franche-Comté University, UPRES EA4266, SFR FED 4234, CHRU Besançon, France.
authors.forename: Wasim
authors.initials: W
authors.lastname: Abbas
authors.affiliation: Laboratory of Molecular Virology, IBMM, Université Libre de Bruxelles (ULB), Gosselies, Belgium.
authors.forename: Sophie
authors.initials: S
authors.lastname: Bouchat
authors.affiliation: Laboratory of Molecular Virology, IBMM, Université Libre de Bruxelles (ULB), Gosselies, Belgium.
authors.forename: Jean-Stéphane
authors.initials: JS
authors.lastname: Gatot
authors.affiliation: Department of Virology, Pathogens &Inflammation Laboratory, University of Franche-Comté, COMUE Bourgogne Franche-Comté University, UPRES EA4266, SFR FED 4234, CHRU Besançon, France.
authors.forename: Sébastien
authors.initials: S
authors.lastname: Pasquereau
authors.affiliation: Department of Infectious Diseases, CHU St-Pierre, ULB, Bruxelles, Belgium.
authors.forename: Kabamba
authors.initials: K
authors.lastname: Kabeya
authors.affiliation: Department of Infectious Diseases, CHU St-Pierre, ULB, Bruxelles, Belgium.
authors.forename: Nathan
authors.initials: N
authors.lastname: Clumeck
authors.affiliation: Department of Infectious Diseases, CHU St-Pierre, ULB, Bruxelles, Belgium.
authors.forename: Stéphane
authors.initials: S
authors.lastname: De Wit
authors.affiliation: Laboratory of Molecular Virology, IBMM, Université Libre de Bruxelles (ULB), Gosselies, Belgium.
authors.forename: Carine
authors.initials: C
authors.lastname: Van Lint
authors.affiliation: Department of Virology, Pathogens &Inflammation Laboratory, University of Franche-Comté, COMUE Bourgogne Franche-Comté University, UPRES EA4266, SFR FED 4234, CHRU Besançon, France.
authors.forename: Georges
authors.initials: G
authors.lastname: Herbein
mesh_terms: D000328:Adult; D001681:Biological Assay; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects* / Q000276:immunology / Q000821:virology; D004279:DNA, Viral / Q000037:antagonists & inhibitors / Q000235:genetics; D005260:Female; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology / Q000821:virology; D017320:HIV Protease Inhibitors / Q000494:pharmacology*; D015497:HIV-1 / Q000187:drug effects* / Q000201:enzymology / Q000235:genetics / Q000254:growth & development; D006801:Humans; D008297:Male; D008875:Middle Aged; D061251:Primary Cell Culture; D011446:Prospective Studies; D012367:RNA, Viral / Q000037:antagonists & inhibitors / Q000235:genetics; D018894:Reverse Transcriptase Inhibitors / Q000494:pharmacology; D019562:Viral Load / Q000187:drug effects; D014775:Virus Activation / Q000187:drug effects*; D017735:Virus Latency / Q000187:drug effects* / Q000235:genetics
chemical_list: D004279:DNA, Viral; D017320:HIV Protease Inhibitors; D012367:RNA, Viral; D018894:Reverse Transcriptase Inhibitors